The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia.
作者信息
Godwin Colin D, Laszlo George S, Wood Brent L, Correnti Colin E, Bates Olivia M, Garling Eliotte E, Mao Zhengwei J, Beddoe Mary E, Lunn Margaret C, Humbert Olivier, Kiem Hans-Peter, Walter Roland B
机构信息
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.
出版信息
Leukemia. 2020 Sep;34(9):2479-2483. doi: 10.1038/s41375-020-0755-7. Epub 2020 Feb 18.
Abstract
摘要
相似文献
1
The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia.缺乏外显子2的CD33剪接异构体作为人类急性髓系白血病的治疗靶点。
Leukemia. 2020 Sep;34(9):2479-2483. doi: 10.1038/s41375-020-0755-7. Epub 2020 Feb 18.
2
Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia.人急性髓系白血病中CD33转录变体的表达及功能特性
Oncotarget. 2016 Jul 12;7(28):43281-43294. doi: 10.18632/oncotarget.9674.
3
CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.CD33特异性嵌合抗原受体T细胞对人类急性髓系白血病表现出强大的临床前活性。
Leukemia. 2015 Aug;29(8):1637-47. doi: 10.1038/leu.2015.52. Epub 2015 Feb 27.
4
Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells.用首个完全人源化双特异性CD33-CD3抗体重定向T细胞可有效清除急性髓系白血病母细胞，而不损害造血干细胞。
Leukemia. 2013 Apr;27(4):964-7. doi: 10.1038/leu.2013.18. Epub 2013 Jan 17.
5
Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms.新型 CD33 抗体揭示了 CD33 异构体的定位、生物学和治疗意义。
Future Oncol. 2021 Jan;17(3):263-277. doi: 10.2217/fon-2020-0746. Epub 2020 Dec 24.
6
Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2.通过CRISPR/Cas9删除CD33外显子2在正常造血过程中构建对CD33靶向免疫疗法的抗性
Leukemia. 2019 Mar;33(3):762-808. doi: 10.1038/s41375-018-0277-8. Epub 2018 Oct 5.
7
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.双特异性 T 细胞接合抗体 AMG 330 对 CD33 靶点的验证和长期培养中 AML 白血病细胞的持续耗竭。
Blood. 2014 Jan 16;123(3):356-65. doi: 10.1182/blood-2013-08-523548. Epub 2013 Dec 3.
8
SRSF1 and PTBP1 Are -Acting Factors That Suppress the Formation of a CD33 Splicing Isoform Linked to Alzheimer's Disease Risk.SRSF1 和 PTBP1 是抑制与阿尔茨海默病风险相关的 CD33 剪接异构体形成的反式作用因子。
Mol Cell Biol. 2019 Aug 27;39(18). doi: 10.1128/MCB.00568-18. Print 2019 Sep 15.
9
CD33 expression on natural killer cells is a potential confounder for residual disease detection in acute myeloid leukemia by flow cytometry.CD33 表达于自然杀伤细胞，可能对流式细胞术检测急性髓系白血病微小残留病造成干扰。
Cytometry B Clin Cytom. 2020 Mar;98(2):174-178. doi: 10.1002/cyto.b.21846. Epub 2019 Oct 17.
10
CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A.CD33 剪接位点基因型与接受抗 CD33 药物偶联物 SGN-CD33A 治疗的患者的结局无关。
J Hematol Oncol. 2019 Aug 22;12(1):85. doi: 10.1186/s13045-019-0771-0.
引用本文的文献
1
CAR-T cell therapy for cancer: current challenges and future directions.用于癌症治疗的嵌合抗原受体T细胞疗法：当前挑战与未来方向
Signal Transduct Target Ther. 2025 Jul 4;10(1):210. doi: 10.1038/s41392-025-02269-w.
2
Targeting the membrane-proximal domain of CD33 to maximize the efficacy of natural killer cell-based immunotherapies.靶向CD33的膜近端结构域以最大化基于自然杀伤细胞的免疫疗法的疗效。
Haematologica. 2025 May 1;110(5):1197-1201. doi: 10.3324/haematol.2024.286593. Epub 2025 Jan 16.
3
Optimizing Siglec-8-Directed Immunotherapy for Eosinophilic and Mast Cell Disorders.优化针对嗜酸性粒细胞和肥大细胞疾病的Siglec-8定向免疫疗法。
Cancers (Basel). 2024 Oct 14;16(20):3476. doi: 10.3390/cancers16203476.
4
Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapy.靶向CD33的膜近端C2结构域以改进嵌合抗原受体T细胞疗法。
Mol Ther Oncol. 2024 Jul 31;32(3):200854. doi: 10.1016/j.omton.2024.200854. eCollection 2024 Sep 19.
5
CRISPR/Cas9 gene editing clarifies the role of CD33 SNP rs12459419 in gemtuzumab ozogamicin-mediated cytotoxicity.CRISPR/Cas9 基因编辑阐明了 CD33 SNP rs12459419 在吉妥珠单抗奥佐米星介导的细胞毒性中的作用。
Int J Hematol. 2024 Aug;120(2):194-202. doi: 10.1007/s12185-024-03803-2. Epub 2024 Jun 10.
6
Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing.药物调控的 CD33 靶向 CAR T 细胞使用临床优化的雷帕霉素剂量控制 AML。
J Clin Invest. 2024 Mar 19;134(9):e162593. doi: 10.1172/JCI162593.
7
Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET CC-96191.CD33/CD16a/NKG2D免疫调节三联自然杀伤细胞工程细胞（TriNKET）CC-96191抗白血病活性的临床前特征分析
Cancers (Basel). 2024 Feb 22;16(5):877. doi: 10.3390/cancers16050877.
8
Pseudogene-Mediated Gene Conversion After CRISPR-Cas9 Editing Demonstrated by Partial Conversion with .经 CRISPR-Cas9 编辑后通过. 部分转换证明的假基因介导的基因转换
CRISPR J. 2021 Oct;4(5):699-709. doi: 10.1089/crispr.2021.0052. Epub 2021 Sep 23.
9
Nanoparticles for Targeted Drug Delivery to Cancer Stem Cells: A Review of Recent Advances.用于靶向给药至癌症干细胞的纳米颗粒：近期进展综述
Nanomaterials (Basel). 2021 Jul 5;11(7):1755. doi: 10.3390/nano11071755.
10
T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia.靶向 CD33 IgV 和 IgC 结构域的 T 细胞衔接双特异性抗体治疗急性髓系白血病。
J Immunother Cancer. 2021 May;9(5). doi: 10.1136/jitc-2021-002509.
Zotero 插件